首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 製藥企業 > 吉利德科技(Gilead Sciences):製藥企業分析報告
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

吉利德科技(Gilead Sciences):製藥企業分析報告

Gilead Sciences: Pipeline * Products * Performance * Potential

出版商 Espicom Business Intelligence
出版日期 2010年02月 商品編碼 51223
內容資訊 英文 Pages: 72
價格
US $ 1040 Hard Copy
US $ 1040 PDF by E-mail (Single user license)
US $ 1040 Web Access (Single user license)


吉利德科技(Gilead Sciences):製藥企業分析報告 是由出版商Espicom Business Intelligence在2010年02月所出版的。 這份英文市場調查報告書包含Pages: 72 價格從美金1040起跳。

目錄

Abstract

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercialises ethical drugs. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products.

Gilead' s HIV product portfolio remains its strongest asset, generating 81.2 per cent of total company sales in 2008. Atripla and Truvada are expected have combined sales approaching US$5 billion by 2013, and will remain the main growth drivers for the company in the foreseeable future. Beyond the HIV portfolio, AmBisome and Hepsera remain important products for Gilead and are forecast to contribute strongly to sales. In addition, the acquisition of Myogen has provided Gilead with exclusive rights to Letairis, which was launched for pulmonary hypertension in the US and Europe in 2007 and 2008 respectively. Initial sales of Letairis have been promising, further validating Gilead' s move into non-virology fields. Viread is the only major product forecast to experience declining sales, and this can be attributed to cannibalisation effects caused by the success of Atripla and Truvada. Seeking to maximise the value of Viread, Gilead is looking to launch the product for the treatment of hepatitis B. The acquisition of Raylo Chemicals and Nycomed' s Irish subsidiary provides Gilead with the manufacturing facilities and infrastructure to meet growing demand for all its products, especially the new HIV combination drugs.

It would seem Gilead' s gamble seems justifiable, with the acquisitions providing the company with the tools for long-term growth. One remaining significant threat to this growth is Gilead' s reliance on its key agreements with other pharmaceutical companies. In 2007, royalty and contract revenue accounted for 11.8 per cent of company revenue, and much of this can be attributed to improved sales of Tamiflu by Roche. This contribution has been reduced to 4.7 per cent of company revenue in fiscal 2008 due to lower demand for Tamiflu. Further declines are anticipated. Furthermore. Atripla has already been cited as a key product for future growth, however, its success will depend on the working relationship between Bristol-Myers Squibb, Merck & Co and Gilead, who are working in a three-way joint venture centred on the marketing of this product.

This new strategic analysis report Gilead Sciences: Pipeline " Products " Performance " Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Table of Contents

Contents

  • Latest Results

EXECUTIVE SUMMARY

  • Introduction
  • Current Financial Position
    • Company Performance
    • Business Segment Performance
    • Geographic Segment Performance
  • Company Strategy
  • Mergers, Acquisitions and Divestitures
    • Key Agreements
      • Discontinued Agreements
    • Employees
  • Product Performance Forecasts
  • Pipeline Analysis
  • Conclusions/Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

ANTIVIRAL

  • Marketed Products
    • HIV
      • Atripla
      • Truvada
      • Viread
      • Others
    • Hepatitis
      • Hepsera
  • R&D Projects
    • HIV
      • Elvitegravir (GS 9137)
      • GS 9350
    • Hepatitis
      • GS 9190
      • GS 9450
    • Discontinued R&D Projects
  • Growth Forecast
    • HIV
    • Hepatitis

OTHERS

  • Marketed Products
    • AmBisome
    • Letairis/Volibris
    • Others
  • R&D Projects
    • Aztreonam lysine
    • Cicletanine
    • Darusentan
    • GS 9219
    • GS 9310/11
    • GS 9411
  • Growth Forecast

APPENDI X 1 - FINANCIAL PERFORMANCE

APPENDI X 2 - KEY CORPORATE EVEN TS

  • 4AZA Bioscience
  • Achillion Pharmaceuticals
  • Anadys Pharmaceuticals
  • Aspen Pharmacare
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Chimerix
  • Dainippon Sumitomo Pharma
  • Diatos
  • Emory University/Royalty Pharma
  • Gladstone Institute of Virology and
  • Immunology
  • GlaxoSmithKline
  • Graceway Pharmaceuticals
  • International Partnership for Microbicides/
  • CONRAD
  • Japan Tobacco
  • Johnson & Johnson
  • LG Life Sciences Ltd
  • Merck & Co
  • Monogram Biosciences
  • Novartis
  • Parion Sciences Inc
  • Roche

APPENDI X 4 - IN FRASTRUCTURE

  • Research and Development Facilities
  • Manufacturing Facilities

APPENDI X 5 - KEY PHARMACE UTICAL SUBSIDIA RIE S / JOIN T VEN TURES

  • Subsidiaries
  • Joint Ventures

APPENDI X 6 - PRODUCT INDE X

Index of Tables

  • Principal Operating Results
  • R&D Expenses by Function
  • Sales By Destination
  • Recent Product Approvals
  • Major Products, Therapeutic Areas and Sales
  • Major HIV Products, 2008
  • Major Hepatitis Products, 2008
  • Major Other Area Products, 2008
  • Full Year Results 2008

Index of Charts

  • R&D Expenses by Function, 2008
  • Sales By Destination
  • Top Selling Products, 2008
  • Atripla Sales (2003A-2013E)
  • Truvada Sales (2003A-2013E)
  • Viread Sales (2003A-2013E)
  • Hepsera Sales (2003A-2013E)
  • GS 9137 Sales (2009A-2013E)
  • HIV Product Portfolio Forecast (2006A-2011E)
  • AmBisome Sales (2002A-2012E)
  • Letairis Sales (2003-2013)
  • Aztreonam Sales (2009E-2012E)
  • Darusentan Sales (2009E-2013E)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity
Back to Top